Valproate as a mainstay of therapy for pediatric epilepsy

Pediatric Drugs

Volumn 8, Issue 2, 2006, Pages 113-129

  Guerrini, Renzo ^a  

^a DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CHRONO; CLOZAPINE; CORTICOSTEROID; DEPAKINE CHRONOSPHERE; DIAZEPAM; ETHOSUXIMIDE; FELBAMATE; LAMOTRIGINE; LORAZEPAM; NEUROLEPTIC AGENT; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORCLOZAPINE; NORTRIPTYLINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TOPIRAMATE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZIDOVUDINE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE; ADD ON THERAPY; ANOREXIA; ANTICONVULSANT THERAPY; APATHY; ATAXIA; BENIGN CHILDHOOD EPILEPSY; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BRAIN ATROPHY; BRAIN DISEASE; CEREBELLUM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMA; COMPARATIVE STUDY; CONFUSION; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SOLUTION; DRUG TOLERABILITY; EPILEPTIC STATE; FATTY LIVER; FEBRILE CONVULSION; FIBRINOGEN DEFECT; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; GLUCURONIDATION; GRAND MAL EPILEPSY; HAIR DISEASE; HAIR LOSS; HUMAN; HYPERAMMONEMIA; JAUNDICE; JUVENILE MYOCLONIC EPILEPSY; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; META ANALYSIS; METABOLIC DISORDER; MONOTHERAPY; MOOD DISORDER; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; NAUSEA; NEUROTOXICITY; PANCREATITIS; PATIENT COMPLIANCE; PHOTOSENSITIVE EPILEPSY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; ROLANDIC EPILEPSY; SEDATION; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; STUPOR; SYSTEMATIC REVIEW; TABLET; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; TONIC SEIZURE; TOXIC HEPATITIS; TREMOR; VOMITING; WEIGHT GAIN;

ANTICONVULSANTS; CHILD; DRUG MONITORING; EPILEPSY; HUMANS; VALPROIC ACID;

EID: 33645848937     PISSN: 11745878     EISSN: 11745878     Source Type: Journal    
DOI: 10.2165/00148581-200608020-00004     Document Type: Review

References (148)

1. Cowan L. The epidemiology of the epilepsies in children. Ment Retard Dev Disabil Res Rev 2002; 8: 171-81
2. Forsgren L. Incidence and prevalence. In: Wallace SJ, Farrell K, editors. Epilepsy in children. 2nd ed. London: Arnold, 2004: 21-5
3. Engel Jr J. International League Against Epilepsy (ILAE): a proposed diagnostic scheme for people with epileptic seizures and with epilepsy. Report of the ILAE Task Force on classification and terminology. Epilepsia 2001; 42: 796-803
4. Loiseau J, Picot MC, Loiseau P. Prognosis of epileptic syndromes: EPIGIR study. In: Jallon P, editor. Prognosis of epilepsies. London: John Libbey, 2003: 29-38
5. Berg A. Identification of epilepsy syndromes at diagnosis and modification with time. In: Jallon P, editor. Prognosis of epilepsies. London: John Libbey, 2003: 185-96
6. Fisher A, Patsalos PN. Pharmacology of antiepileptic drugs. In: Wallace SJ, Farrell K, editors. Epilepsy in children. 2nd ed. London: Arnold, 2004: 358-83
7. Roger J, Bureau M, Dravet C, et al., editors. Epileptic syndromes in infancy, childhood, and adolescence. 3rd ed. London: John Libbey, 2002
8. Arzimanoglou A, Guerrini R, Aicardi J. Aicardi's epilepsy in children. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2004
9. Guerrini R, Andermann E, Avoli M, et al. Cortical dysplasias, genetics and epileptogenesis. Adv Neurol 1999; 79: 95-121
10. Holmes GL, Stafstr̈om CE. Effects of seizures on the developing brain. In: Tuxhorn I, Holthausen H, Boenigk H, et al., editors. Pediatric epilepsy syndromes and their surgical treatment. Paris: John Libbey, 1997: 489-504
11. Loring DW, Meador KJ. Cognitive side effects of antiepileptic drugs in children. Neurology 2004; 62: 872-7
12. Dulac O, Guerrini R. Seizure types and syndromes: lumping and splitting. Epilepsia Res 2001; 45: 37-40
13. Loescher W. Valproic acid: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. New York: Lippincott Williams & Wilkins, 2002: 767-79
14. Löscher W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem Res 1993; 18: 485-502
15. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999; 58: 31-59
16. Perucca E, Gatti G, Frigo GM, et al. Pharmacokinetics of valproic acid after oral and intravenous administration. Br J Clin Pharmacol 1978a; 5: 313-8
17. Perucca E, Gatti G, Frigo GM, et al. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978b; 5: 495-9
18. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714
19. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-72
20. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid: 1988. Clin Pharmacokinet 1988; 15: 367-89
21. Barre J, Berger Y. Pharmacokinetics of a newly developed sustained-release form of sodium valproate. Proceedings of the Fourth International Symposium on Sodium Valproate and Epilepsy; 1989 Apr 26-28; London
22. Dulac O, Alvarez JC. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration. Pharmacotherapy 2005; 25 (1): 35-41
23. Levy RH, Shen DD, Abbott FS, et al. Valproic acid: chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 3-22
24. Dickinson RG, Hooper WD, Dunstan PR, et al. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther Drug Monit 1989; 11: 127-33
25. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 1977; 21: 736-43
26. Herngren L, Lundberg B, Nergardh A. Pharmacokinetics of total and free valproic acid during monotherapy in infants. J Neurol 1991; 238: 315-9
27. Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants: age-related differences and therapeutic implications. Clin Pharmacokinet 1980; 5: 485-527
28. Hall K, Otten N, Irvine-Meek J, et al. First-dose and steady-state pharmacokinetics of valproic acid in children with seizures. Clin Pharmacokinet 1983; 8: 447-55
29. Goulden KJ, Dooley JM, Camfield PR, et al. Clinical valproate toxicity induced by acetylsalicylic acid. Neurology 1987; 37: 1392-4
30. Levy RH, Koch KM. Drug interactions with valproic acid. Drugs 1982; 24: 543-56
31. Dulac O, Steru D, Rey E, et al. Sodium valproate monotherapy in childhood epilepsy. Brain Dev 1986; 8: 47-52
32. Wilder BJ, Karas BJ, Penry JK, et al. Gastrointestinal tolerance of divalproex sodium. Neurology 1983; 33: 808-11
33. Bergmann A, Schmidt D, Hutt HJ, et al. Epilepsietherapie mit retardierter Valproinsäure: Erfahrungen mit 1172 Patienten [results of a pragmatic study on 1172 patients treated with Depakine chrono]. Aktuelle Neurologie 1999; 26: 121-6
34. Rentmeester T, Hulsman J. Sustained release valproate versus conventional formulation valproate: a study of the tolerance and efficacy of LA 40220. Proceedings of the Fourth International Symposium on Sodium Valproate and Epilepsy; 1989 Apr 26-28; London
35. Dodson WE. Level off. Neurology 1989; 39: 1009-10
36. Allarakhia IN, Garofalo EA, Komarynski MA, et al. Valproic acid and thrombocytopenia in children: a case-controlled retrospective study. Pediatr Neurol 1996; 14: 303-7
37. Guerrini R, Arzimanoglou A, Brower O. Rationale for treating epilepsy in children. Epileptic Disord 2002b; 4 Suppl. 2: S9-21
38. Pinder RM, Brogden RN, Speight TM, et al. Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs 1977; 13: 81-123
39. Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group. Neurology 1997; 48: 182-8
40. Erenberg G, Rothner AD, Henry CE, et al. Valproic acid in the treatment of intractable absence seizures in children. Am J Dis Child 1982; 136: 526-9
41. Gram L, Wulff K, Rasmussen KE, et al. Valproate sodium: a controlled clinical trial including monitoring of drug levels. Epilepsia 1977; 18: 141-7
42. Sato S, White BG, Penry JK, et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32: 157-63
43. Callaghan N, O'Hare J, O'Driscoll D, et al. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol 1982; 24: 830-6
44. Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999; 40: 973-9
45. Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2003; (3): CD003032
46. Perucca E. The management of refractory idiopathic epilepsies. Epilepsia 2001; 42 Suppl. 3: 31-5
47. Guerrini R. Epilepsy in children. Lancet 2006; 367: 499-524
48. Verity CM, Hosking G, Easter DJ, et al. A multicenter comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995; 37: 97-108
49. de Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotheapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-13
50. Thilothammal N, Banu K, Ratnam R. Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study. Indian Pediatr 1996; 33: 549-55
51. Pavone L, Incorpora G, La Rosa M, et al. Treatment of infantile spasms with sodium dipropylacetic acid. Dev Med Child Neurol 1981; 23: 454-61
52. Bachman DS. Use of valproic acid in treatment of infantile spasms. Arch Neurol 1982; 39: 49-52
53. Siemes H, Spohr HL, Michael T, et al. Therapy of infantile spasms with valproate: results of a prospective study. Epilepsia 1988; 29: 553-60
54. Prats JM, Garaizar C, Rua MJ, et al. Infantile spasms treated with high doses of sodium valproate: initial response and follow-up. Dev Med Child Neurol 1991; 33: 617-25
55. Fisher E, Siemes H, Pund R, et al. Valproate metabolism in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity. Epilepsia 1992; 33: 165-71
56. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982; 23: 582-93
57. Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate: a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982; 65: 504-23
58. Schmidt D, Bourgeois B. A. risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Saf 2000; 22: 467-77
59. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998; 19 Suppl. 3: S2-10
60. Papini M, Pasquinelli A, Armellini M, et al. Alertness and incidence of seizures in patients with Lennox-Gastaut syndrome. Epilepsia 1984; 25: 161-7
61. Tassinari CA, Dravet C, Roger J, et al. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 1972; 13: 431-5
62. Guerrini R, Bonanni P, Parmeggiani L, et al. Pathophysiology of myoclonic epilepsies. Adv Neurol 2005; 95: 23-46
63. Medina MT, Martinez-Juarez IE, Duron RM, et al. Treatment of myoclonic epilepsies of childhood, adolescence, and adulthood. Adv Neurol 2005; 95: 307-23
64. Dulac O, Kaminska A. Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes. J Child Neurol 1997 Nov; 12 Suppl. 1: S23-8
65. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39: 508-12
66. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine [letter]. Neurology 2000; 55: 1758
67. Oguni H, Tanaka T, Hayashi K, et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002; 33: 122-32
68. Lin Y, Itomi K, Takada H, et al. Benign myoclonic epilepsy in infants: video-EEG features and long-term follow-up. Neuropediatrics 1998 Oct; 29 (5): 268-71
69. Tennison MB, Greenwood RS, Miles MV. Methsuximide for intractable childhood seizures. Pediatrics 1991; 87: 186-9
70. Lortie A, Chiron C, Mumford J, et al. The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology 1993; 43 Suppl. 5: S24-7
71. Kaminska A, Ickowicz A, Plouin P, et al. Delineation of cryptogenic Lennox-Gastaut syndrome and myoclonic astatic epilepsy using multiple correspondence analysis. Epilepsy Res 1999; 36: 15-29
72. Guerrini R, Parmeggiani L, Shewmon A, et al. Motor dysfunction resulting from epileptic activity involving the sensory-motor cortex. In: Guerrini R, Aicardi J, Andermann F, et al., editors. Epilepsy and movement disorders. Cambridge: Cambridge University Press, 2002: 77-96
73. Marini C, Parmeggiani L, Masi G, et al. Nonconvulsive status epilepticus precipitated by carbamazepine presenting as dissociative and affective disorders in adolescents. J Child Neurol 2005 Aug; 20 (8): 693-6
74. Dravet C, Bureau M. Benign myoclonic epilepsy in infancy. In: Roger J, Bureau M, Dravet C, et al., editors. Epileptic syndromes in infancy childhood and adolescence. 3rd ed. London: John Libbey, 2002: 69-79
75. Aicardi J, Levy Gomes A. The myoclonic epilepsies of childhood. Cleve Clin J Med 1989; 59: S34-9
76. Guerrini R, Genton P. Epileptic syndromes and visually induced seizures. Epilepsia 2004; 45 Suppl. 1: 14-8
77. Kasteleijn-Nolst Trenite DG, Guerrini R, Binnie CD, et al. Visual sensitivity and epilepsy: a proposed terminology and classification for clinical and EEG phenomenology. Epilepsia 2001; 42: 692-701
78. Guerrini R, Dravet C, Genton P, et al. Idiopathic photosensitive occipital lobe epilepsy. Epilepsia 1995; 36: 883-91
79. Ishiguro Y, Takada H, Watanabe K, et al. A follow-up survey on seizures induced by animated cartoon TV program 'pocket monster'. Epilepsia 2004; 45: 377-83
80. Dravet C, Bureau M, Oguni H, et al. Severe myoclonic epilepsy in infancy (Dravet syndrome). In: Roger J, Bureau M, Dravet C, et al., editors. Epileptic syndromes in infancy childhood and adolescence. 3rd ed. London: John Libbey, 2002: 81-103
81. Covanis A, Stodieck SR, Wilkins AJ. Treatment of photosensitivity. Epilepsia 2004; 45 Suppl. 1: 40-5
82. Deonna T. Cognitive and behavioral manifestations of epilepsy in children. In: Wallace SJ, Farrell K, editors. Epilepsy in children. 2nd ed. London: Arnold, 2004: 250-7
83. Deonna TW. Acquired epileptiform aphasia in children (Landau-Kleffner syndrome). J Clin Neurophysiol 1991; 8: 288-98
84. Paetau R, Kajola M, Korkman M, et al. Landau-Kleffner syndrome: epileptic activity in the auditory cortex. Neuroreport 1991; 2: 201-4
85. Deonna T, Davidoff V, Maeder-Ingvar M, et al. The spectrum of acquired cognitive disturbances in children with partial epilepsy and continuous spike-waves during sleep: a 4-year follow-up case study with prolonged reversible learning arrest and dysfluency. Eur J Paediatr Neurol 1997; 1: 19-29
86. Lewine JD, Andrews R, Chez M, et al. Magnetoencephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders. Pediatrics 1999; 104 (3 Pt 1): 405-18
87. Massa R, de Saint-Martin A, Carcangiu R, et al. EEG criteria predictive of complicated evolution in idiopathic rolandic epilepsy. Neurology 2001; 57: 1071-9
88. De Saint-Martin AD, Carcangiu R, Arzimanoglou A, et al. Semiology of typical and atypical Rolandic epilepsy: a video-EEG analysis. Epileptic Disord 2001; 3: 173-82
89. Parmeggiani L, Seri S, Bonanni P, et al. Electrophysiological characterization of spontaneous and carbamazepine-induced epileptic negative myoclonus in benign childhood epilepsy with centro-temporal spikes. Clin Neurophysiol 2004; 115: 50-8
90. Gordon K, Bawden H, Camfield P, et al. Valproic acid treatment of learning disorder and severely epileptiform EEG without clinical seizures. J Child Neurol 1996; 11: 41-3
91. Levy RH, Shen DD. Valproic acid: absorption, distribution and excretion. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press Ltd, 1995: 605-17
92. Yasuhara A, Yoshida H, Hatanaka T, et al. Epilepsy with continuous spike-waves during slow sleep and its treatment. Epilepsia 1991; 32: 59-62
93. Van Lierde A. Therapeutic data. In: Beaumanoir A, Bureau M, Deonna T, et al., editors. Continuous spikes and waves during slow sleep. London: John Libbey, 1995: 225-7
94. Billard C, Autret A, Laffont F, et al. Acquired aphasia in epileptic children: four cases with electrical infraclinic status epilepticus during sleep. Rev Electroencephalogr Neurophysiol Clin 1981; 11: 457-67
95. Larrieu JL, Lagueny A, Ferrer X, et al. Epilepsy with continuous discharges during slow-wave sleep: treatment with clobazam. Rev Electroencephalogr Neurophysiol Clin 1986; 16: 383-94
96. De Negri M. Electrical status epilepticus in childhood: neuropsychological impairment and therapeutic management. Dev Med Child Neurol 1994; 36: 183-6
97. Boel M, Casaer P. Continuous spikes and waves during slow sleep: a 30 month follow-up study of neuropsychological recovery and EEG findings. Neuropediatrics 1989; 20: 176-80
98. Marescaux C, Hirsch E, Finck S, et al. Landau-Kleffner syndrome: a pharmacologic study of five cases. Epilepsia 1990; 31: 768-77
99. Lerman P, Lerman-Sagie T, Kivity S. Effect of early corticosteroid therapy for Landau-Kleffner syndrome. Dev Med Child Neurol 1991; 33: 257-60
100. Wallace S. Febrile seizures. In: Wallace SJ, Farrell K, editors. Epilepsy in children. 2nd ed. London: Arnold, 2004: 123-30
101. Herranz JL, Armijo JA, Arteaga R. Effectiveness and toxicity of phenobarbital, primidone, and sodium valproate in the prevention of febrile convulsions, controlled by plasma levels. Epilepsia 1984; 25: 89-95
102. Mamelle N, Mamelle JC, Plasse JC, et al. Prevention of recurrent febrile convulsions: a randomized therapeutic assay: sodium valproate, phenobarbital and placebo. Neuropediatrics 1984; 15: 37-42
103. Lee K, Melchior JC. Sodium valproate versus phenobarbital in the prophylactic treatment of febrile convulsions in childhood. Eur J Pediatr 1981; 137: 151-3
104. Newton RW. Randomised controlled trials of phenobarbitone and valproate in febrile convulsions. Arch Dis Child 1988; 63: 1189-91
105. Rantala H, Tarkka R, Uhari M. A meta-analytic review of the preventive treatment of recurrences of febrile seizures. J Pediatr 1997; 131: 922-5
106. Farwell JR, Lee YJ, Hirtz DG, et al. Phenobarbital for febrile seizures: effects on intelligence and on seizure recurrence. N Engl J Med 1990; 322: 364-9
107. Wallace SJ, Smith JA. Successful prophylaxis against febrile convulsions with valproic acid or phenobarbitone. BMJ 1980; 280: 353-4
108. Alvarez L, Dunoyer C, Gilman J, et al. Safety and dose/level relationship in rapid intravenous loading of valproic acid in children under age 12 years [abstract]. Epilepsia 1999; 40 Suppl. 7: 143
109. Alfonso I, Alvarez LA, Gilman J, et al. Intravenous valproate dosing in neonates. J Child Neurol 2000; 15: 827-9
110. O'Hara KA, Morton LD, Meloche NM, et al. Intravenous valproate experience in pediatric patients less than 32 months of age [abstract]. Epilepsia 2000; 41 Suppl. 7: 87
111. Werz MA, Goyal M, Reed RC, et al. Intravenous valproic acid: adult and pediatric clinical experience [abstract]. Epilepsia 2000; 41 Suppl. 7: 214-5
112. Morton LD, Towne AR, Garnett LK, et al. Safety and efficacy of intravenous valproate in status epilepticus [abstract]. Epilepsia 2000; 41 Suppl. 7: 252
113. Katragadda SB, Aluri BC, Burdette DE. Intravenous administration of valproate in 12 patients [abstract]. Epilepsia 2000; 41 Suppl. 7: 3
114. Überall MA, Trollmann R, Wunsiedler U, et al. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology 2000; 54: 2188-9
115. Eeg-Olofsson O, Lindskog U. Acute intoxication with valproate. Lancet 1982; 8284: 1306
116. Capocchi G, Balducci A, Cecconi M, et al. Valproate-induced epileptic tonic status. Seizure 1998; 7: 237-41
117. Legarda SB, Booth MP, Fennell EB, et al. Altered cognitive functioning in children with idiopathic epilepsy receiving valproate monotherapy. J Child Neurol 1996; 11: 321-30
118. Schmidt D. Adverse effects of valproate. Proceedings 'valproate modern perspectives', Satellite Symposium 15th Epilepsy International Symposium; 1983 Sep; Washington, DC, USA. Epilepsia 1984; 25 Suppl. 1: S44-9
119. Forsythe I, Butler R, Berg I, et al. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol 1991; 33: 524-34
120. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled cross-over design. Am J Psychiatry 2000; 157: 818-20
121. Richens A, Davidson DLW, Cartlidge NEF, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Neurol Neurosurg Psychiatry 1994; 57: 682-7
122. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults: the Department of the Veteran Affairs Epilepsy Cooperative Study Group. N Engl J Med 1992; 327: 765-71
123. Guerrini R, Bonanni P, Patrignani A, et al. Autosomal dominant cortical myoclonus and epilepsy (ADCME) with complex partial and generalized seizures: a newly recognized epilepsy syndrome with linkage to chromosome 2p11.1-q12.2. Brain 2001; 124: 2459-75
124. Terada K, Ikeda A, Mima T, et al. Familial cortical tremor as a unique form of cortical reflex myoclonus. Mov Disord 1997; 12: 370-7
125. Guerrini R, De Lorey T, Bonanni P, et al. Cortical myoclonus in Angelman syndrome. Ann Neurol 1996; 40: 39-48
126. Grosse P, Guerrini R, Parmeggiani L, et al. Abnormal corticomuscular and intermuscular coupling in cortical myoclonus. Brain 2003; 126: 326-42
127. Beghi E, Bizzi A, Codegoni AM, et al. Valproate, carnitine metabolism, and biochemical indicators of liver function. Epilepsia 1990; 33: 346-52
128. De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 1998; 39: 1216-25
129. Guerrini R, Belmonte A, Canapicchi R, et al. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia 1998; 39: 27-32
130. Verrotti A, Greco R, Morgese G, et al. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res 1999; 29: 36-40
131. Mercke Y, Sheng H, Khan T, et al. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000; 12: 35-42
132. Altunbasak S, Biatmakoui F, Baytok V, et al. Serum and hair zinc levels in epileptic children taking valproic acid. Biol Trace Elem Res 1997; 58 (1-2): 117-25
133. Good CR, Feaster CS, Krecko VF. Tolerability of oral loading of divalproex sodium in child psychiatry inpatients. Child Adolesc Psychopharmacol 2001; 11: 53-7
134. Dinesen H, Gram L, Anderson T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65-9
135. Genton P, Bauer J, Duncan S, et al. On the association between valproate and polycystic ovarian syndrome. Epilepsia 2001; 42: 295-304
136. Bryant III AE, Dreifuss FE. Valproic acid hepatic fatalities: III. US experience since 1986. Neurology 1996; 46: 465-9
137. Moreiras Plaza M, Rodrigues Goyanes G, Cuina L, et al. On the toxicity of valproic acid. Clin Nephrol 1999; 51: 187-9
138. Konig SA, Siemes H, Blacker F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994; 35: 1005-15
139. Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate induced hepatotoxicity. Neurology 2001; 56: 1505-9
140. Asconape JJ, Penry JK, Dreifuss FE, et al. Valproate-associated pancreatitis. Epilepsia 1993; 34: 177-83
141. Buzan RD, Fireston D, Thomas M, et al. Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. J Clin Psychiatry 1995; 56: 529-32
142. Verrotti A, Greco R, Matera V, et al. Platelet count and function in children receiving sodium valproate. Pediatr Neurol 1999b; 21: 611-4
143. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22: 62-5
144. Chambers HG, Weinstein CH, Mubarak SJ, et al. The effect of valproic acid on blood loss in patients with cerebral palsy. J Pediatr Othop 1999; 19: 792-5
145. Anderson GD, Lyn YX, Berge C, et al. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1977; 87: 252-6
146. Genton P, Gelisse P. Valproic acid: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 837-51
147. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs: I. Treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252-60
148. Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 1999; 33: 247-62